Pulmokine Overview
- Year Founded
-
2007

- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$20M
Pulmokine General Information
Description
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.
Contact Information
Website
www.pulmokine.netCorporate Office
- 7 University Place
- Room B127
- Rensselaer, NY 12144
- United States
Corporate Office
- 7 University Place
- Room B127
- Rensselaer, NY 12144
- United States
Pulmokine Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Merger/Acquisition | 26-Nov-2024 | $20M | Completed | Generating Revenue | ||
6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
5. Grant | 01-Jan-2017 | Completed | Generating Revenue | |||
4. Grant | 01-Jan-2016 | Completed | Generating Revenue | |||
3. Seed Round | 04-Mar-2015 | Completed | Generating Revenue | |||
2. Debt - General | 01-Oct-2014 | Completed | Generating Revenue | |||
1. Grant | 01-Jan-2014 | $1.5M | Completed | Generating Revenue |
Pulmokine Comparisons
Industry
Financing
Details
Pulmokine Competitors (29)
One of Pulmokine’s 29 competitors is Insmed, a Formerly VC-backed company based in Bridgewater, NJ.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Insmed | Formerly VC-backed | Bridgewater, NJ | ||||
Lung Therapeutics | Formerly VC-backed | Austin, TX | ||||
Cortalix | Venture Capital-Backed | Groningen, Netherlands | ||||
Artizan Biosciences | Venture Capital-Backed | New Haven, CT | ||||
hVIVO | Formerly VC-backed | London, United Kingdom |
Pulmokine Patents
Pulmokine Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210038510-A1 | Formulations of kinase inhibitors and prostanoids | Inactive | 08-Feb-2018 | ||
US-20180117039-A1 | Combination therapy for treating pulmonary hypertension | Active | 27-Oct-2016 | ||
EP-3532063-A1 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | ||
US-20200261448-A1 | Combination therapy for treating pulmonary hypertension | Active | 27-Oct-2016 | ||
CA-3041679-A1 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | A61K31/497 |
Pulmokine Former Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Broadview Ventures | Venture Capital | Minority | ||
National Heart, Lung, and Blood Institute | Government | |||
National Institute Of Allergy and Infectious Diseases | Government |
Pulmokine FAQs
-
When was Pulmokine founded?
Pulmokine was founded in 2007.
-
Where is Pulmokine headquartered?
Pulmokine is headquartered in Rensselaer, NY.
-
What industry is Pulmokine in?
Pulmokine’s primary industry is Biotechnology.
-
Is Pulmokine a private or public company?
Pulmokine is a Private company.
-
What is the current valuation of Pulmokine?
The current valuation of Pulmokine is
. -
What is Pulmokine’s current revenue?
The current revenue for Pulmokine is
. -
How much funding has Pulmokine raised over time?
Pulmokine has raised $1M.
-
Who are Pulmokine’s investors?
Broadview Ventures, National Heart, Lung, and Blood Institute, and National Institute Of Allergy and Infectious Diseases have invested in Pulmokine.
-
Who are Pulmokine’s competitors?
Insmed, Lung Therapeutics, Cortalix, Artizan Biosciences, and hVIVO are some of the 29 competitors of Pulmokine.
-
When was Pulmokine acquired?
Pulmokine was acquired on 26-Nov-2024.
-
Who acquired Pulmokine?
Pulmokine was acquired by Xoma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »